Assistant Prof in Residence
M_Diabetes Center
Dr. Quandt is an endocrinologist at UCSF and the San Francisco VA with particular interest in endocrine autoimmune disease like type 1 diabetes and endocrine complications of cancer treatments, particularly immunotherapy. She does clinical and translational research trying to better understand who gets these complications and why. She is the clinical lead for adults eligible for teplizumab, an immunotherapy approved to delay the onset of type 1 diabetes.
Publications
Investigating the influence of baseline medications on immune checkpoint inhibitor treatment outcomes for cancer patients 3706.
The Journal of Immunology
MON-362 Endocrine Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy: Insights Across Cancer Types and Treatment Stages.
Journal of the Endocrine Society
SUN-565 High-dimensional Immunophenotyping of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes.
Journal of the Endocrine Society
Abstract IA05: Endocrine organs in the crosshairs of the immune system.
Cancer immunology research
Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.
Journal for immunotherapy of cancer
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study.
Cancer research communications
From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes.
Current diabetes reports
Abstract PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study.
Clinical Cancer Research
The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.
Journal of diabetes science and technology
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study.
Journal for immunotherapy of cancer
Abstract 2276: Whole exome sequencing of immune-mediated colitis in cancer patients treated with immune checkpoint inhibitors.
Cancer research
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.
Cold Spring Harbor perspectives in medicine
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Journal for immunotherapy of cancer
irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.
medRxiv : the preprint server for health sciences
Polyfunctional IL-21+ IFNG+ T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy.
bioRxiv : the preprint server for biology
67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity.
Annals of Oncology
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
medRxiv : the preprint server for health sciences
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.
Journal of Clinical Oncology
HLA associations with immunotherapy related endocrine toxicity.
Journal of Clinical Oncology
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
Journal of Clinical Oncology
Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
Cancer research
Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
The Journal of experimental medicine
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Nature communications
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
NPJ breast cancer
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Frontiers in endocrinology
Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
The oncologist
Genetic prediction of colitis in non-small cell lung cancer patients on immune checkpoint inhibitor therapy.
medRxiv : the preprint server for health sciences
Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
Frontiers in endocrinology
Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
Journal of Clinical Oncology
The cognitive load of inpatient consults involving immune-related adverse events.
Journal of Clinical Oncology
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Journal of the Endocrine Society
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
Nature biotechnology
Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
Journal of Clinical Oncology
Evaluating survival following severe immune-related adverse events requiring hospitalization.
Journal of Clinical Oncology
Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.
Journal of Clinical Oncology
Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq.
bioRxiv : the preprint server for biology
Patient-Centered Diabetes Care of Cancer Patients.
Current diabetes reports
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Checkpoint Inhibitor–Induced Diabetes.
Diabetes in Practice
Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes.
Diabetes in Practice
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.
Annual review of medicine
Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus.
Journal of the Endocrine Society
SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events.
Journal of the Endocrine Society
SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus.
Journal of the Endocrine Society
SUN-298 Spectrum of Imaging in Immune Checkpoint Inhibitor Induced Hypophysitis.
Journal of the Endocrine Society
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
Clinical and experimental immunology
Chapter 19 Thyroid Disorders During Pregnancy, Postpartum, and Lactation.
Maternal-Fetal and Neonatal Endocrinology
Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma.
The Journal of clinical investigation
Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.
The lancet. Diabetes & endocrinology
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.
Cancer immunology research
Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.
Journal of Clinical Oncology
Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).
Journal of Clinical Oncology
Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
Molecular and clinical oncology
The association of alcohol consumption with mammographic density in a multiethnic urban population.
BMC cancer
Association of age, stature, and education with ocular dimensions in an older white population.
Archives of ophthalmology (Chicago, Ill. : 1960)